Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is New Ray Medicine International Holding Days Payable?
New Ray Medicine International HoldingHKSE:06108 52 Days Payable is 30.85 as of Dec. 2025, which is 39% below its 10-year median of 50.65. GuruFocus rates HKSE:06108 with a GF Score™ of 52/100 and a GF Value™ of HK$1.04 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 612 Healthcare Providers & Services companies, New Ray Medicine International Holding ranks worse than 51.96% on this metric.
HKSE:06108's Days Payable is ranked worse than 51.96% of 612
companies
in the Healthcare Providers & Services industry
Industry Median: 56.91
vs HKSE:06108: 53.87
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding Days Payable Chart
New Ray Medicine International Holding Annual Data
New Ray Medicine International Holding Days Payable Competitor Comparison
For the Pharmaceutical Retailers subindustry, New Ray Medicine International Holding's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Ray Medicine International Holding Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, New Ray Medicine International Holding's Days Payable distribution charts can be found below:
* The bar in red indicates where New Ray Medicine International Holding's Days Payable falls into.
New Ray Medicine International Holding Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding (HKSE:06108) has a Days Payable of 30.85 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on New Ray Medicine International Holding and its competitors. This is 39% below median its historical median of 50.65. Over the past decade, New Ray Medicine International Holding's Days Payable has ranged from 3.35 to 104.62. According to the industry distribution chart, New Ray Medicine International Holding ranks #318 out of 612 companies in the Healthcare Providers & Services industry, placing it in the top 52%.
Is New Ray Medicine International Holding's Days Payable too high?
New Ray Medicine International Holding's current Days Payable of 30.85 is 39% below median its 10-year median of 50.65. Over the past 10 years, this metric has ranged from a low of 3.35 to a high of 104.62. The Healthcare Providers & Services industry median Days Payable is 56.91. New Ray Medicine International Holding's value of 30.85 is 45.8% below this industry median. Based on the distribution chart, New Ray Medicine International Holding ranks #318 out of 612 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, New Ray Medicine International Holding has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does New Ray Medicine International Holding's Days Payable compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, New Ray Medicine International Holding ranks #318 out of 612 companies for Days Payable. This places New Ray Medicine International Holding in the lower half of its industry. The industry median Days Payable is 56.91. New Ray Medicine International Holding's value of 30.85 is 45.8% below this benchmark. Historically, New Ray Medicine International Holding's own Days Payable has ranged from 3.35 to 104.62 over the past decade. While the company's 10-year median is 50.65 vs. the industry median of 56.91, New Ray Medicine International Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 56.91, based on 612 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. New Ray Medicine International Holding's current Days Payable of 30.85 is 45.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on New Ray Medicine International Holding and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 56.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. New Ray Medicine International Holding's current Days Payable is 30.85, which is 39% below median its own 10-year median of 50.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Ray Medicine International Holding stock overvalued right now?
Based on GuruFocus' analysis, New Ray Medicine International Holding (HKSE:06108) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.04, compared to a current price of HK$0.23 — trading 78.4% below its estimated fair value. The current Days Payable is 30.85, which is 39% below median its 10-year median of 50.65 and 45.8% below the Healthcare Providers & Services industry median of 56.91. New Ray Medicine International Holding's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For New Ray Medicine International Holding (HKSE:06108), the current Days Payable is 30.85 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is New Ray Medicine International Holding (HKSE:06108) Overvalued in 2026?
Based on GuruFocus' analysis, New Ray Medicine International Holding stock appears to be undervalued.
The current stock price of HK$0.23 is trading 78.4% below its estimated GF Value™ of HK$1.04.
GuruFocus considers New Ray Medicine International Holding to be Possible Value Trap.
Key valuation signals for HKSE:06108:
Days Payable: 30.85 (39% below median its 10-year median of 50.65)
GF Value™: HK$1.04 vs. price of HK$0.23 (78.4% below fair value)
Industry Position: 45.8% below the Healthcare Providers & Services median (#318 of 612)
No single metric tells the full story. See the HKSE:06108 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
New Ray Medicine International Holding Ltd is engaged in the trading and distribution of pharmaceutical products in the People's Republic of China. The company's segments include the Distribution and trading of pharmaceutical products and the Provision of marketing and promotion services. Distribution and trading of pharmaceutical products segment consist of Injection drugs and generate maximum revenue for the company.
52GF Score
Get the complete analysis for HKSE:06108
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06108 has been successfully added to your 
